A Study of Safety and Efficacy of Tildacerfont in Females With Polycystic Ovary Syndrome and Elevated Adrenal Androgens
A Randomized, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of Tildacerfont in Adult Subjects With Polycystic Ovary Syndrome (PCOS) and Elevated Adrenal Androgens
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Clinical Trials
- Phone Number: 415-655-4169
- Email: POWER@sprucebiosciences.com
Study Locations
-
-
California
-
Sacramento, California, United States, 95817
- Spruce Study Site
-
San Francisco, California, United States, 94158
- Spruce Study Site
-
-
Connecticut
-
New Haven, Connecticut, United States, 06519
- Spruce Study Site
-
-
Florida
-
Clearwater, Florida, United States, 33759
- Spruce Study Site
-
Lake Worth, Florida, United States, 33461
- Spruce Study Site
-
Miami, Florida, United States, 33173
- Spruce Study Site
-
Winter Park, Florida, United States, 32792
- Spruce Study Site
-
-
Idaho
-
Idaho Falls, Idaho, United States, 83404
- Spruce Study Site
-
-
Kansas
-
Wichita, Kansas, United States, 67226
- Spruce Study Site
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Spruce Study Site
-
Fall River, Massachusetts, United States, 02720
- Spruce Study Site
-
-
Michigan
-
Southfield, Michigan, United States, 48034
- Spruce Study Site
-
-
New York
-
Williamsville, New York, United States, 14221
- Spruce Study Site
-
-
North Carolina
-
Raleigh, North Carolina, United States, 27612
- Spruce Study Site
-
-
Ohio
-
Cincinnati, Ohio, United States, 45219
- Spruce Study Site
-
Cleveland, Ohio, United States, 44106
- Spruce Study Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Spruce Study Site
-
-
Texas
-
Bedford, Texas, United States, 76022
- Spruce Study Site
-
Houston, Texas, United States, 77024
- Spruce Study Site
-
Houston, Texas, United States, 77030
- Spruce Study Site
-
-
West Virginia
-
Morgantown, West Virginia, United States, 26506
- Spruce Study Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Female subjects aged 18 to 40 years old at Screening visit
- Diagnosis of PCOS (either historical or during Screening) according to NIH (1990) criteria
- DHEAS level > age-matched upper limit of normal (ULN) at Screening visit
- Agree to follow industry standard contraception guidelines within protocol
Exclusion Criteria:
Evidence of:
- History of congenital adrenal hyperplasia (CAH), Cushing's syndrome, pituitary or adrenal disease
- Clinically significant hyperprolactinemia
- Thyroid stimulating hormone (TSH) <0.1 mU/mL or >4.5mU/mL at Screening
- Cortisol levels concerning for adrenal insufficiency
- Other findings suggestive of secondary cause for anovulation and/or hyperandrogenemia
- Total testosterone levels >140 ng/dL, DHEAS >650 mcg/dL, virilization or other signs or symptoms concerning for ovarian hyperthecosis or androgen-secreting tumors
- Medical conditions that require glucocorticoid treatment within 30 days of screening and throughout the duration of the study
- Clinically significant unstable medical conditions, illness, or chronic diseases
- Prior hysterectomy or bilateral oophorectomy
- Females who are pregnant or nursing
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Treatment with Tildacerfont
Subjects randomized in this arm received 4 weeks of 50 mg of oral tildacerfont tablet, followed by 4 weeks of 100 mg oral tildacerfont tablet, and then 4 weeks of 200 mg oral tildacerfont tablet for a total of 12 weeks of treatment.
|
Oral tablet formulation taken once daily.
Other Names:
|
|
Placebo Comparator: Placebo Control Arm
Subjects randomized in this arm received 12 weeks of oral matched-placebo tablet
|
Non-active dosage form taken once daily.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in DHEAS
Time Frame: 12 weeks (assessed at Baseline, Weeks 4, 8 and 12)
|
To evaluate the effect of tildacerfont in changing (reducing) DHEAS in subjects with PCOS and elevated adrenal androgens
|
12 weeks (assessed at Baseline, Weeks 4, 8 and 12)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Reduction in DHEAS
Time Frame: 12 weeks (assessed at Baseline, Weeks 4, 8 and 12)
|
Number of subjects with >/=30% change from baseline in DHEAS
|
12 weeks (assessed at Baseline, Weeks 4, 8 and 12)
|
|
Normalization of DHEAS
Time Frame: 12 weeks (assessed at Baseline, Weeks 4, 8 and 12)
|
Number of subjects with DHEAS =/< upper limit of normal for DHEAS
|
12 weeks (assessed at Baseline, Weeks 4, 8 and 12)
|
|
Number of Subjects With TEAE as Assessed by CTCAE Version 5
Time Frame: 12 weeks (assessed at Baseline, Weeks 4, 8 and 12)
|
Evaluation of safety of tildacerfont with PCOS as measured by number of subjects with adverse events following dosing by CTCAE Version 5
|
12 weeks (assessed at Baseline, Weeks 4, 8 and 12)
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Will Charlton, MD, Spruce Biosciences
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urogenital Diseases
- Genital Diseases
- Endocrine System Diseases
- Neoplasms
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Genital Diseases, Female
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Ovarian Cysts
- Cysts
- Polycystic Ovary Syndrome
- Adrenal Gland Diseases
Other Study ID Numbers
Other Study ID Numbers
- SPR001-210
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.